Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.
Location: Canada, British Columbia, Vancouver
Employees: 51-200
Total raised: $85M
Founded date: 2018
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.02.2021 | Series A | $85M | - |
Mentions in press and media 13
| Date | Title | Description |
| 04.12.2024 | Hedge Funds and Healthcare: A New Frontier in Investment Strategy | In the world of finance, the dance between risk and reward is a constant. Recently, a new partner has joined the fray: healthcare expertise. Major hedge funds are turning to doctors and scientists, seeking an edge in the volatile pharmaceut... |
| 03.12.2024 | NanoVation Therapeutics: Funding Round Led By Convergent Ventures Completed | NanoVation Therapeutics, a company developing innovative technologies to overcome barriers to nucleic acid delivery, announced the expansion of its Board of Directors and the close of a funding round led by Convergent Ventures. These two de... |
| 28.08.2023 | Notch Therapeutics closes Vancouver lab, will focus on Toronto and Seattle offices | Notch Therapeutics announced that it will shut down its lab in Vancouver, B.C., and lay off about 25 employees, with some offered relocation options. “Our goal is to build on core capabilities in Toronto and Seattle as we continue to develo... |
| 27.02.2023 | Notch Researchers Develop Improved Model for Predicting CAR-T Clinical Pharmacology and Response to Advance Next-Generation Product Design; Results Published in Nature Biotechnology | VANCOUVER, BC, Feb. 27, 2023 /PRNewswire/ -- Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the publication of a study in Natur... |
| 09.08.2021 | Here are your 2021 Life Sciences BC Award winners | Dr. Carl Hansen, CEO, AbCellera Life Sciences BC (LSBC) announced the recipients of the 23rd Annual Life Sciences BC Awards. Every year, the awards recognize individuals and organizations who contribute to the vibrant life sciences ecosyste... |
| 17.02.2021 | Notch Therapeutics raises $85M for cancer treatments and plans to open Seattle location | Notch Therapeutics is commercializing technologies developed in the labs of Juan-Carlos Zúñiga-Pflücker, left, chair of Notch’s scientific advisory board, and Chief Scientific Officer Peter Zandstra. (University of Toronto and Notch Photos)... |
| 15.02.2021 | Notch Therapeutics Closes $85M Series A Financing | Notch Therapeutics, Inc., a Vancouver, BC-based biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, closed an U.S. $85m Series A financing. The round was led by an exclusively ... |
| 11.02.2021 | VC Daily: Notch Therapeutics Grabs $85 Million to Push New Cancer-Cellular Therapies | Good day. Corporate and venture-capital investors have pumped $85 million into Notch Therapeutics Inc., a Canadian startup seeking to push cancer-cellular therapy in a new direction. New cell therapies for cancer, called CAR-T, use a patien... |
| 10.02.2021 | Lumira portfolio company Notch therapeutics closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies | VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/ — Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S... |
| 21.02.2020 | OBIO’s Niagara Investment Summit showcases Canadian Healthcare Innovation | Earlier this month, 43 of the most promising companies in the Canadian health science industry came together at the OBIO Niagara Investment Summit, where they showcased their innovations to over 40 investors from across North America and Ja... |
Show more